Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Approves Regeneron/Roche MAb Cocktail For COVID-19

Product Still Under Rolling Review At European Medicines Agency

Executive Summary

The UK has pipped the EU to the post in granting a marketing authorization to what the health secretary describes as “a significant addition to our armoury to tackle COVID-19.”

You may also be interested in...



UK Nod For Pfizer’s COVID-19 Oral Treatment

Pfizer’s Paxlovid is the second take-at-home COVID-19 treatment approved for use in the UK.

EMA Greenlights Ronapreve & Regkirona For COVID-19 In EU

The European Commission is likely to act rapidly on the formal approval of coronavirus treatments casirivimab/imdevimab and regdanvimab.

European Countries Call For Health Technology Assessments Of COVID-19 Products

Value assessments of COVID-19 monoclonal antibodies should inform pricing decisions, says cross country coalition.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS144827

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel